Asymmetric porphycenes: Synthesis and photophysical properties of 9-substituted 2,7,12,17-tetraphenylporphycenes

Journal of Porphyrins and Phthalocyanines

Volumn 13, Issue 3, 2009, Pages 376-381

  Arad, Ofir ^a   Rubio, Noemí ^a,b   Sánchez García, David ^a   Borrell, José I ^a   Nonell, Santi ^a  

^a INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

photodynamic therapy; photosensitizers; porphycenes; porphyrinoids; singlet oxygen

Indexed keywords

EID: 78649868137     PISSN: 10884246     EISSN: None     Source Type: Journal    
DOI: 10.1142/S1088424609000462     Document Type: Article

References (24)

1. Vogel E, Köcher M, Schmickler H and Lex J. Angew. Chem. Int. Ed. Engl. 1986; 25: 257-259.
2. Sá nchez-Garcí a D and Sessler JL. Chem. Soc. Rev. 2008; 37: 215-232.
3. Richert C, Wessels JM, Müller M, Kisters M, Benninghaus T and Goetz AE. J. Med. Chem. 1994; 37: 2797-2807.
4. Stockert JC, Cañete M, Juarranz A, Villanueva A, Horobin RW, Borrell JI, Teixidó J and Nonell S. Curr. Med. Chem. 2007; 14: 997-1026.
5. Braslavsky SE, Müller M, Martire DO, Pörting S, Bertolotti SG, Chakravorti S, Koç-Weier G, Knipp B and Schaffner K. J. Photochem. Photobiol., B. 1997; 40: 191-198.
6. Arad O, Morros J, Batllori X, Teixidó J, Nonell S and Borrell JI. Org. Lett. 2006; 8: 847.
7. Vogel E, Koch PA, Rahbar A and Cross AD. Preparation of porphycenes useful in photodynamic therapy or as intermediates for synthesis of photoactivatable dyes suitable for photodynamic therapy. Cytopharm, Inc. USA. 92-US364(9212636), 39. 6-8-1992. WO. 1-29-1992.
8. Vogel E, Benninghaus T, Richert C, Müller M and Cross AD. Preparation of porphycene compounds for photodynamic therapy. Cytopharm, Inc. USA. 92-US4624(9300087), 76. 7-1-1993. WO. 6-5-1992.
9. Vogel E, Müller M, Halpern O and Cross AD. Preparation of 9-substituted porphycenes as photosensitizers. Cytopharm, Inc. USA. 96-US4177(9631452), 30. 10-10-1996. WO. 4-4-1996.
10. Vogel E, Müller M, Halpern O and Cross AD. Preparation of porphycene esters and amides for use in photodynamic therapy. Cytopharm, Inc. USA. 96-US4176(9631451), 36. 10-10-1996. WO. 4-4-1996.
11. Vogel E, Müller M, Halpern O and Cross AD. Synthesis of C-9 ethers of porphycenes for use in the photodynamic therapy (PDT) treatment of cancer, dermatological conditions and diseases associated with hyperproliferative tissue generally. 97-US17918(9815271), 62. 4-16-1998. WO. 10-9-1997.
12. Hennig W. Neuartige Pyrrolische Porphyrinoide und Ihre Metallkomplexe. Doctoral Thesis, Universität zu Köln: Köln, 1992.
13. Nonell S, Bou N, Borrell JI, Teixidó J, Villanueva A, Juarranz A and Cañete M. Tetrahedron Lett. 1995; 36: 3405-3408.
14. Cañete M, Lapeña M, Juarranz A, Vendrell V, Borrell JI, Teixidó J, Nonell S and Villanueva A. Anticancer Drug Des. 1997; 12: 543-554.
15. Cañete M, Ortiz A, Juarranz A, Villanueva A, Nonell S, Borrell JI, Teixidó J and Stockert JC. Anticancer Drug Des. 2000; 15: 143-150.
16. Villanueva A, Cañete M, Nonell S, Borrell JI, Teixidó J and Juarranz A. Anticancer Drug Des. 1996; 11: 89-99.
17. Gavaldá A, Borrell JI, Teixidó J, Nonell S, Arad O, Grau R, Cañete M, Juarranz A, Villanueva A and Stockert JC. J. Porphyrins Phthalocyanines 2001, 5: 846.
18. Darwent JR, Douglas P, Harriman A, Porter G and Richoux MC. Coord. Chem. Rev. 1982; 44: 83-126.
19. Jiménez-Banzo A, Ragàs X, Kapusta P and Nonell S. Photochem. Photobiol. Sci. 2008; 7: 1003-1010.
20. Nonell S and Braslavsky SE. Methods Enzymol. 2000; 319: 37-49.
21. Wilkinson F, Helman WP and Ross AB. J. Phys. Chem. Ref. Data 1993; 22: 113-262.
22. Arbogast JW, Darmanyan AP, Foote CS, Diederich FN, Whetten RL, Rubin Y, Alvarez MM and Anz SJ. J. Phys. Chem. 1991; 95: 11-12.
23. Porter HK. Org. React. 1973; 20: 455.
24. Rubio N, Prat F, Bou N, Borrell JI, Teixidó J, Villanueva A, Juarranz A, Cañete M, Stockert JC and Nonell S. New J. Chem. 2005; 29: 378-384.